Akari Therapeutics, Plc
AKTX
$1.07
-$0.04-3.60%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -- | 12.38M | 12.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 19.02M | 17.73M |
| Operating Income | -- | -- | -- | -19.02M | -17.73M |
| Income Before Tax | -- | -- | -- | -9.95M | -9.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | -9.95 | -9.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -9.95M | -9.32M |
| EBIT | -- | -- | -- | -19.02M | -17.73M |
| EBITDA | -- | -- | -- | -19.02M | -17.73M |
| EPS Basic | -- | -- | -- | -4.36K | -4.20K |
| Normalized Basic EPS | -- | -- | -- | -1.36 | -1.31 |
| EPS Diluted | -- | -- | -- | -4.37K | -4.20K |
| Normalized Diluted EPS | -- | -- | -- | -1.36 | -1.31 |
| Average Basic Shares Outstanding | -- | -- | -- | 17.61M | 17.27M |
| Average Diluted Shares Outstanding | -- | -- | -- | 8.60K | 8.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
